<SEC-DOCUMENT>0001144204-13-035481.txt : 20130618
<SEC-HEADER>0001144204-13-035481.hdr.sgml : 20130618
<ACCEPTANCE-DATETIME>20130618163107
ACCESSION NUMBER:		0001144204-13-035481
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20130618
ITEM INFORMATION:		Entry into a Material Definitive Agreement
FILED AS OF DATE:		20130618
DATE AS OF CHANGE:		20130618

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apollo Medical Holdings, Inc.
		CENTRAL INDEX KEY:			0001083446
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		IRS NUMBER:				870042699
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0131

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-25809
		FILM NUMBER:		13919750

	BUSINESS ADDRESS:	
		STREET 1:		450 NORTH BRAND BLVD.,
		STREET 2:		SUITE 600
		CITY:			GLENDALE
		STATE:			CA
		ZIP:			91203
		BUSINESS PHONE:		818-507-4617

	MAIL ADDRESS:	
		STREET 1:		700 N. BRAND BLVD.,
		STREET 2:		SUITE 450
		CITY:			GLENDALE
		STATE:			CA
		ZIP:			91203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SICLONE INDUSTRIES INC
		DATE OF NAME CHANGE:	19990413
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v347803_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):
June 18, 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>APOLLO MEDICAL HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; padding-right: 0.8pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Delaware</FONT></TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 33%; padding-right: 0.8pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">000-25809</FONT></TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 33%; padding-right: 0.8pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>20-8046599</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(State or Other Jurisdiction</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Commission File</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(I.R.S. Employer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">of Incorporation)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Number)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Identification Number)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">700 N. Brand Blvd., Suite 220, Glendale,
CA 91203</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)
(zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(818) 396-8050</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Registrant's telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 1.01 Entry into a Material Definitive Agreement.
</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 5, 2013, Apollo Medical Holdings, Inc. issued a press
release announcing  the formation of a new operating unit, Maverick Medical Group, Inc. The press release is furnished
herewith as Exhibit 99.1.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD STYLE="width: 95%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Press Release of Apollo Medical Holdings, Inc. dated June 5, 2013</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>APOLLO MEDICAL HOLDINGS, INC.</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 51%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dated: &nbsp;&nbsp;June 18, 2013</FONT></TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 44%; border-bottom: black 1pt solid; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/ Warren Hosseinion</I></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Warren Hosseinion</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v347803_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red"><IMG SRC="logo1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>apollo
medical HOLDINGS ANNOUNCES Launch OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>NEW
OPERATING UNIT: MAVERICK MEDICAL GROUP</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">GLENDALE, CA - (PR Newswire) &ndash; June
5, 2013 - <U>Apollo Medical Holdings, Inc.</U> ("ApolloMed") (OTCQB:AMEH), an integrated physician-driven healthcare delivery
company that puts &lsquo;Patients First,&rsquo; today announced the launch of a new operating unit, Maverick Medical Group, an
Independent Physician Association (IPA) serving Medicare, Dual Eligible, Commercial and Medi-Cal patients residing in the Greater
Los Angeles area.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;The launch of Maverick IPA is both
a logical and strategic complement to our existing businesses. Maverick enables ApolloMed to more fully capture value from our
hospitalists&rsquo; high quality, cost effective performance, as well as to leverage the growing ApolloMed ACO care community,&rdquo;
stated Warren Hosseinion, M.D., Chief Executive Officer of ApolloMed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Maverick is an equity-sharing IPA providing
physicians with the support to meet the challenges inherent in the operation of individual physician practices. Maverick operates
under full and professional risk contracts with health plans through its network of over 150 Primary Care Physicians and Specialist
physicians. Maverick offers its physician partners a full complement of provider benefits, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">IPA equity ownership with no buy-in required</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Competitive monthly capitation payments</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Opportunities to participate on the IPA
Board and Committees</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Access to all financial reporting, ensuring
optimal transparency</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Positioned for the Dual-Eligible Pilot
Program in Los Angeles County </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Maverick has succeeded in contracting for
Medicare Advantage, Special Needs, Commercial and Medi-Cal HMOs serving the Greater Los Angeles market. Committed to delivering
superior coordinated care and a positive patient-physician experience, Maverick will provide its members with direct access to
Specialists; transportation for its senior members; a dedicated, toll-free &ldquo;Senior Line&rdquo; answered by a live person;
comprehensive health and wellness education and preventative care scheduling assistance; multi-lingual/multi-cultural customer
service representatives; multiple laboratory draw centers and urgent care centers; and access to local contracted hospitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Apollo Medical Holdings, Inc.
(ApolloMed)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">Headquartered
in Glendale, California and dedicated to putting the &lsquo;Patient First,&rsquo; ApolloMed is a physician-driven integrated healthcare
delivery company, fueled by its commitment to provide exceptional multi-disciplinary care in the communities it serves in Southern
and Central California.&nbsp; ApolloMed is addressing the healthcare needs of the nation&rsquo;s largest population center by
leveraging its integrated healthcare delivery platform through its affiliated physician groups:&nbsp; ApolloMed Hospitalists,
ApolloMed ACO (Accountable Care Organization) and Maverick Medical Group IPA.&nbsp; This platform combines hospitalist medicine,
critical care medicine, patient care coordination, case management and transition management&nbsp;that enable healthcare organizations
to engage in performance payments for utilization efficiency, quality of care objectives and shared accountability arrangements.&nbsp;&nbsp;ApolloMed
strives to improve medical outcomes with high quality, cost efficient care.&nbsp;&nbsp;For more information, please visit&nbsp;</FONT><FONT STYLE="color: Black"><B><U>www.apollomed.net</U></B><U>.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><I>Page <B>1</B> of <B>2</B></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><I><B>&nbsp;</B></I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This press release may contain forward-looking
statements, including information about management's view of future expectations, plans and prospects for Apollo Medical Holdings,
Inc. (&ldquo;the Company&rdquo;).&nbsp; In particular, when used in the preceding discussion, the words &ldquo;predicts,&rdquo;
&quot;believes,&quot; &quot;expects,&quot; &quot;intends,&quot; &ldquo;seeks,&rdquo; &ldquo;estimates,&rdquo; &quot;plans,&quot;
&quot;anticipates,&quot; and similar conditional expressions or future or conditional verbs such as &ldquo;will,&rdquo; &ldquo;may,&rdquo;
&ldquo;might,&rdquo; &ldquo;should,&rdquo; &ldquo;would&rdquo; and &ldquo;could&rdquo; are intended to identify forward-looking
statements.&nbsp; In addition, our representatives may from time to time make oral forward-looking statements. Any such statements,
other than those of historical fact, about an action, event or development, are forward-looking statements.&nbsp;Such statements
are based on the current expectations and certain assumptions of the Company&rsquo;s management. Such statements are, therefore,
subject to a variety of known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company,
which could cause the actual results, performance or achievements of the Company, its subsidiaries and concepts to be materially
different than those that may be expressed or implied in such statements or anticipated on the basis of historical trends.&nbsp;
Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company&rsquo;s
actual results, performance or achievements may vary materially from those described in the relevant forward-looking statement
as being expected, anticipated, intended, planned, believed, sought, estimated or projected. Unknown or unpredictable factors also
could have material adverse effects on the Company&rsquo;s future results.&nbsp; The forward-looking statements included herein
are made only as of the date hereof.&nbsp; The Company cannot guarantee future results, levels of activity, performance or achievements.&nbsp;
Accordingly, you should not place undue reliance on these forward-looking statements.&nbsp; Finally, the Company undertakes no
obligation to update or revise these forward-looking statements to reflect the impact of circumstances or events that arise after
the date the forward-looking statement was made, except as required by law, and also takes no obligation to update or correct information
prepared by third parties that are not paid for by the Company. You should not place undue reliance on any forward-looking statement
and should consider the uncertainties and risks discussed under Item 1A. &ldquo;Risk Factors&rdquo; of the Company&rsquo;s Annual
Report on Form 10-K for the year ended January 31, 2013 and in any of the Company&rsquo;s other subsequent Securities and Exchange
Commission filings.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR ADDITIONAL INFORMATION, PLEASE CONTACT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>HANOVER|ELITE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Kathy Addison, Chief Operating Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">407-585-1080 or via email at<FONT STYLE="color: #365F91">
</FONT><FONT STYLE="color: Black"><B><U>AMEH@hanoverelite.com</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red"><IMG SRC="logo2.jpg" ALT=""></P>



<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><I>Page <B>2</B> of <B>2</B></I></P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo1.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!]`5L#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHSC
MK1G/>@`SU]J1Y5B0LS!0.Y.!7%_%_P"-.G_"C3E64K/J5Q_J+<'D_P"TWH*\
M='Q>U/Q==F6\NG(<\1(=J*/3%>CALMJUH>TVC^?H<E;&TZ<N3=GTBFHP2,`L
MJ,3Z'-39SSUKQKPGXIV!/G_6O3/#?B!;V-49LDUEB,)*EYFE*NIFS11FBN,W
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBC-`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`!]ZIZ_K,/AO1+S4+A@L%E"T
MSGIPH)JXW3GM7E/[;6OR>'_V7O&%U"V)8;51G.,9D4']#71A*/MJ\*/\S2^]
MV,<36]E2E4[)O[D?(WBWXPW/Q-\=WVM7$CL+N0^2I/$<8/RK^5=!X:\2$%?F
M)Q7@WAS7RBH,]/>OH3]E#X37'QJ\1.TQDBT:PP;F4<%SV0'U/?VK]4S"A2PU
M%REI&*/@\%B)UZB2U;9Z'X+U&6^A$V^.&WC^]<3R"*%/J[8%=##^TIX#\&2I
M%J/C?18Y2VTI&QEP?JN1CWKU'QC\#/"WCWP&?#&J:5%<:,0`;<,4#>Y(P2?K
M7PM^UA_P36E^#MK-KWA3S-3\/J<S6Y7,]D/7C[R#U[=Z^7RV67YA5]EB*CIM
MO165G\W?7RM\SV\QECL'3]IAX*:6^KNOEV^?R/N7P!\</"?CM4BTOQ-HVH2M
M@+&EPJR-[!2<FNSY_&OQ?L/"TNE727-H\MK<1\I+"QC=?H1R*^K/V0_V\M;\
M!W]IX?\`&]S+JFB2L(HK^3)GL^PW'^)?<\UOFW!<Z4'5P<^>W1JS^7?TT.;+
M>*E5DJ>*ARWZK5?/L?>E%16-[%J5G%<02K-#.H>-U.5=2,@BI:^%>FC/L+A1
M7B/[87_!0[X5?L-:-!<>/O$D-E>7G_'MI\"F>[GXX/EKRJ_[1P*^2$_X.<?@
MPVI-"?#?BX0!RHGVQX(_O8SFD!^DM%>)?L>?\%"?A;^W/HEQ<^`/$,5_>62A
MKO3YE,-W;9[E&Y*YXW#(JI^V;_P4;^&7[!DFBI\0]1O;%M>W?9/(M6GW;>N<
M=*`/>**^0+'_`(+D_L^7_P`$-5\>KXHN$TG3+S^SQ!):LMU=3E=P2./J1C&3
MT%>;_"G_`(.1/@3\0/&D&DZK#X@\+074@BBOKV$20%B<#=LR5!]3TH`_0>BJ
MFA:]9^)]&M=1TZZ@OK&]C6:">%P\<J$9#`C@@UX5^V5_P4T^$G[#$4</C?Q$
MBZS<IO@TJT4SW3^F57[@/JV*`/H"BOS>TC_@YL^"M[JR076@>++&V9L-<LD;
MJ@]=H.37VW^S/^UAX#_:^^'J>)_`&OVVN:86V2;/DFMF_NR1GYD/U'-`'R'_
M`,%3O^"T6K_\$\?CCI?A&P\%Z?XBBU"P%X;B>Y>-D)/W<+7JW_!*[_@HMJ'_
M``42^#7B/Q5?^'+3P[+H=\+18()FD64>66R2U?F;_P`'-7_)Z?AO_L!K_.OJ
M#_@V-X_9#^(/_8:'_HDTV!YO\6/^#GGQ)\./'_B?18_AAHURGA_4+BR61KV4
M&41.5#''3.*_67X2^-9/B1\*_#'B*2%;:37]*M=2>%22(C-"DA4'N`6Q^%?R
MF_M1D_\`"]?B1_V'K_\`]&M7]2O[+L@B_9@^'+.0JKX6TTL2<`#[)%S0P.^&
M>_6BOB[]J/\`X+O?`G]F3Q;<^'CJMWXKUNQ<QW-OI*"2.$CJ/-/RD@\8!.*X
MOX4_\'(?P&\?>(X-/U=/$'A1+EQ&ES>P"6(,>FXIG:/<]*0'Z"T5G>&/%NF^
M-?#-GK.D7UMJ6EZA"+BVNK>0213(1D,K#@BO!-6_X*E?";1M;N-/GU._%S;3
MFW<"T<@.&V]?K79A,!B<4VL/3<[;V5['+BL=A\-9XB:C?:[M<^C**^=_C+_P
M4U^&WPBU&.Q%U<ZW?E5>6&R4$0@C(!8\9]JV?V=/V_?`7[2&KOI>FW<VG:PB
M&46=Z`C.@ZE6Z'`[5TSR3'QH?6)49*'>WX^GF<\<YP,JWU>-6+EVO_6I[?17
MS%\3?^"KGPU^'WB6?3+5K_7Y+5S'++9J!$K`\@$_>^HKT_\`9R_:V\'?M/:;
M<2^'+YC>68!N;*9=DT(/?'<>XI8C)<=1H_6*M*2AW:_JWS'1S?!5JOL*55.7
M:_\`5STZBL7QY\0='^&/AFYUG7M0M]-TZT7=)-,P4?0>I]AS7S1XC_X+!_#;
M2M2>&RM-9U2%<XGCC$:MSZ-S48+*<9C$WAJ;DEU2T^\K&9IA,*TL1446^CW^
MX^L:*\<_9Z_;G\`_M(Z@VGZ+J1M]81=_V&Z'ER./]DGAL>@KUO4]4M]%TV>\
MO)X[:UM4,LLLC!4C4#)))Z`"N;$X2OAZGL:\'&79HZ,/BZ->G[6C)2CW3+%?
M/G[=O[:EY^Q_%X9>UT6WUC^WI)T;S9&3RO+53QCKG=7-^,O^"N/PT\,^(I;&
MT35=8AA?8UU;QA8LCJ1GDC^=>`?\%0_C[X8_:*\"?#C6O#&H+>0"XO%EB(VR
MP-L3AEZCGOWKZK(N&\0\=26/HM4Y7WNE\+:O;5'S>=<04%@ZKP59>TC;:S^T
MD_4^HOV$OVUKS]L!?$QN]$M]'_L%X%7RI&?S?,#'G/3&VOH2O@O_`((D\1_$
M8>DUG_Z!)7WI7F<48.CA<SJ4*$>6*M9>L4ST.',75Q.7TZU9WD[W?S:"BBBO
M`/;"BBB@!LTGE1EB>E>5?M%^'_\`A9_P@\5Z`IS)?6#M&HZLT?S@#W.VO1/%
M5[]BT[<3]XXKR_7O%$FG7Z7$9R\+[AGH?8^U>EET)*:JPW337JM3CQCC*#IR
MV::?S/S#T36I8<HZNL\9VLA&&##MCUS7ZL_LJ_#:+X9?`_0[15`N;NW6[N'Q
M\SNX#<^X!`_"OA#]L#]GH^!OB##X_P!"A:X\):Q>I+J"1C<VF3E@7#@=$;D@
M_A7Z0^")H[CP7H\D/^JDLH63_=,:X_2OLN,L?&OA*$J7PR;;\FK:/TO^I\KP
MOA94<35A5WBE;S3OJO6QIX/M3+FTCO+>2&5%DBE4HZ,,JP(P0?:I*/7O7YW<
M^V9^?'[4'[/<?PK^*UW!:1XTS4/])M0.0@)Y7\#FO.CX+W=5)X]*^VOVT_"T
M>LZ5HEQM'G0S2+G'4$#BOG[_`(0QN/E_2OU#*LWG4PL)5'KL_EH?#X_+81KR
M4%I_F>Z?L"_$6YUOP!<^';YWDFT-AY#N<EHFZ+_P'^M>_%L9//%?,?['^D2:
M/\4YU&1'+9.6'J01BOIQW"(68X"C))Z"OA\]A&.,E*&TM?OW_$^HRN4GAXJ7
M30_FS_X*.?#_`.+_`.TI^WI\0-<N_!'C2^MGUQ],TRX&ERO%%9H^R(KQC:%.
M3CK7V7^T1_P0.^&GPD_X)Z:AXSM]8UNW\<:)HL>K37ETX$4LI"%XF3&0N20.
M_2ND_P""D/\`P</M\%_B?K'@?X0Z%IFJW^@SM:W^NZD"UMYJ\.D2+@DJ?XCD
M&OC+XJ>-?VQ_^"@/PGUGQ-XC?Q+)\.;*W-]+YJ"PTMH@,DQG`,@X'!SVKR#T
M#A?^".7Q+U+X9_\`!1?X<7NG330C4KEK&[B5BJW$4BD;6]0,YY[U]O\`_!TZ
M,WWPK]0)_P"9KX`_X)>N'_;_`/A<PS@ZLF/TK[__`.#I[_C]^%GTG_F:'N!\
M<?\`!)?_`()O_P##R/XR:OH>K:U?Z)X5\+6JWU_+:_ZZ5I"458B<J&XY)'2L
M;_@JI_P3^3_@GA^T;!X1LM3NM;T'5[`:CI]U<J/.V%RACDQP6!!Z5]V?\&LF
MGVXL/BC=Y'VQG@B(SSL!)!Q]:Y3_`(.E+2-/BM\,YPBB9[&9"W<J&)Q1U`^@
M_P#@@Q^UW<7G_!,[7W\0W371^%DMU#"&?++9HF^-23[[NM?C;XX\5^*?VV/V
MK;F_U"Y?4/$WCO73!&[$L%#R;55<]%"#H.*^V_\`@DAK-[;?\$R?VKXD5H[>
MWT">6*8#GS##)N&?;`KXS_X)ZN3^VQ\'VR2Q\1VAS^=`'Z&_\%%?^"#'@C]F
M;]AB^\<^$=2UB;Q-X-M8[O57NG#17T7_`"U.T#Y2"1CVKYR_X($?M+:C\#_V
M^_#WA^.Y==%^(@.EW5L6(B,NTNDI'3<-N`?>OVR_X*7V,6I?L!?%B"X1989?
M#MP'1NAX%?ST_P#!,`X_X*%?"`#/R^((\>WRM1T`^J_^#FK_`)/3\-_]@-?Y
MU]0?\&QO_)H?Q!_[#0_]$FOE_P#X.:O^3T_#?_8#7^=?4'_!L;_R:'\0?^PT
M/_1)IO8#\:?VHO\`DNWQ(_[#U_\`^C6K]U/^"D?[4.I?LQ?\$;?#-QH=TUGK
MWB7PSI6D6DRG!19+2+S2.^?+W`8]:_"O]J/_`)+M\2/^P]?_`/HUJ_5'_@OI
M?S6W_!,K]FR%)&6.Y%BLB]G`TM"/UH?0#X;_`."47["\'[?G[5MKX4U>ZO+?
MP[I]L^HZQ<0',S*/NKD]W;@D^M>I?\%MO^"8?AW_`()]>,/">I>#KB^D\+^+
MUE@%O=,':WN8QN8*0.5*$'!YR:]*_P"#7MR/VM?'XSU\/Q9_[^FOH7_@Z1LX
MIOV;OAQ,Z!I8-=G\MNZYA4''U%*X%3_@V1_:6U/QO\&/&_PUU*ZDNHO!DJ7N
MGF1B6B@GR/*7_94KT[;J\'^*!/\`PLW7\?>.HRA>W.\XJY_P:]7$\7[0WQ*B
M2'?!+HT/FR;L>5AS@8[YJG\3O^2HZYG/.IR?^C:_3/#C^)7](_FS\[\0/@H>
MLOT/JJS_`."6<$O[+<WC2]\0W:^)Y+'^TE@`!M57&[8W<MCOFOD?PFNH2^)[
M"'3)YK;4+B<6T,D3E65G.P\CMS^5?KU>?\F4MG)_XIP?^BJ_)CX0G_B['AT9
M/&J1?^C!7T'"^;8G%T\3+$2YN63MHM%9Z>AXG$F68?"SP\:$>7F2OYNZU]3Z
M;_:?_P""8]C^SU^SD_BR#7[R\UC3%1]0AD`^SON."(P!D8)[UY[_`,$R?%=U
MX=_;%\-VULY6/64FM;@9^\@C9P/S`K[N_P""F7_)F7BO_KG'_P"A"OS^_P""
M<W_)ZG@;_KK/_P"B7KCR?,:^/R+$U,7+F?O_`/I-U]S.G-L#1P6=8>&&CRIN
M'_I5OQ1ZK_P5^^,UYXF^,UEX+CG==,T&W2>>!6^62:0;E9A[*<5L?L+_`/!.
M+PU\>O@8OBSQ1<WWFZRSK8K;N%$"*2N[GJVX&O&O^"D%S)=?MG>,&F^\OD(,
MC'RB,`#\JVO@/X?_`&BK[X5Z7+X$NM9C\*L'^PI;R*(P-QW8R/[V:ZOJU2ED
M="EA:T:+:BW)NU[J[5^[?X(YOK-.IG->IB:3JI.244K[.R^27XGD_BS3-3_9
MI^/EU!:3NNI>$]3W03#*LP5LKGZC&?6OO#_@I/\`'F<?L9>'VLK@PS>./*5W
M1L%E"!Y%'J#D@U\H^+/V'OCAXYUV[U75?#=]?ZE>MOGGD<;I3ZGBO7?^"EWA
MN\\(_LL?!;3-1A-O?6,L\4T1Y,;"%<BECWA<7CL#><9SBW>S3VC?[KH>"^LX
M;!XSW)0BTK736\K??9GAO[%'[*Y_:M^*;Z+-=S:=I.GP>?>3P@&15Z*J]@3Z
MFKO[<7[(_P#PR5\0+'3[34+C4M'U:(RVDLW$JD'YE;'!/N/6O<O^")\"2>,?
M'\K+F2.VM55NX!9\_P`A6E_P6UA15^'4NW]XTMXA/<@*A`_,FB>=8E<2+`<W
M[NVWGR\U_4(Y3A_]7WC>7]Y??RYN6WH._P"")/\`J_B+[2V?_H$E?>E?!7_!
M$C/E_$;)S^^L_P#T"2OO6OS[C3_D<5O^W?\`TE'W7"3_`.$JE_V]_P"E,***
M*^6/I`HHHH`POB)`\GAF:1,EH/GP.N*\'\5ZP2&^;G\Z^DYXEN(7C<95P58'
MN#7S9\>?`]WX!U%I0COIMPQ,4H&0O^R?0U[F33@Y>SEOT/-S"+4>='!WWC2?
M1FG6,I+!<*4GMYE#PW"GJK*>H_6O3?`_[<GA_3--MK'6=.GTQ;:-8D:V7S(@
MH&``.H`&!7@'B35<ACG/M7!:_J9PV3G-?8O)Z&*BHU5]VA\V\QJ4&Y0?WGVU
M??MY_#C3HV:35+P[1G"VS$GZ5XQ\</\`@JA%;V$]IX*TJ4S."$OKWY0H(ZB/
MKGZFOE/7]1&6Z#%>D?L??LFW_P"T+XSBU;4X)8/".E2A[B5U*_;6!SY2>N>Y
M[5K'AO*\%3>*Q-VH]WIZ65KM]CEGGN88F:P^'LF^R_7H?2'PRTK6]6^`?AR?
MQ%=7-[K6MR2:M<FX.73S.%7'8`#I5K_A"\'[N?PKUZ]\-+=2@K'Y<<:B.)`.
M(T``"CZ`4R#P/]ID"JO)/4_SKY*69)R<MKMNRV5^GR/J(8)J*AO9)>MNIC?`
M#P5_9NK7>H,NW8GE*<=<]?Y5W_CP2_\`"#:T(`3.;&?RQZMY;8_6KFC:3'HN
MGI;Q#`7J?[Q]:M,H8$$9!X(/>O"Q5=UJCFSTZ--4X**/Y*9;AM/^.:S>(HP/
ML_B))-5C;D;%N5,H/J-H-?O5_P`%%_V_/@IX0_X)V:_I^@^*=!N3XBT);30]
M'TZ9#,ZN%"J$'W0HZY]*\2_;P_X-QW^-OQSUCQI\./%=IH<'B2Y:[OM*O82R
M0S/R[QN/X2?X<<5C?LR_\&QT6@ZW=ZA\3O&,>MPQ6DT-AIUE&5C29D*I*[$_
M=5B#M`YQ6#-3\Z_^"7*&/]OSX6J>2-62OT!_X.G?^/[X5_2?^9J_\`O^#;GQ
MO\`_C9X7\96'Q8TR:X\-ZC%>;#IA!F17!9.O!901GWK._P"#ITG[9\*\CG;/
M_,T`>(?\&^/[;W@[]D[X[^*](\>:M;:%I'B^QC2UU&X;9!;S1L6(D8\*&!P#
MZU@?\%]/VR/"W[6O[5ND1^"=6@USP[X6TO[(U[`=T%Q<%V9BA_B4*0,^U5/^
M"7?_``2WTC_@I/\`!#QU`=8?P[XH\.WD;:??>7YL,BL.8Y$[KZ'L37O'PV_X
M-</%<_BJU3Q1\0],M="C<-<"QMBTTR@\HN<!21W[47`[[_@A)^S?>^/O^"7_
M`,78Y(71O'<M[IUHD@PLRK#@,/8EL9]J_*7X)^-)/V<_VE_#>O7EJXD\&>(5
MEGMY!AAY4I4@CM@<U_4M\"?@EX>_9Q^$NA>"?"UDMCH?A^V6UMHAR<#JS'NQ
M.23[U\&?\%%?^#?#P]^U7\3[_P`=>`_$$?@K7]5)EU*S>V\VSOY?^>@P1Y;'
MO@'-%P.B_P""M7_!1+X9:K_P35\3Q>'O&&C:SJ?Q`TQ=/TZVL[E7G/FX+.5!
MRH7&#GH37Y6?\$2_@U?_`!>_X*/?#S[+"TUKX7N#K.H'!(2%$*\GM\S+7TGI
MW_!KS\2;B]MHKKX@Z%!:[@KR")I#"N>2J_T&*_23_@G!_P`$OO!7_!.;P7=P
M:---KGB?6-O]IZS<H%DFQT1%YV)_LYHN!^7G_!S5_P`GI^&_^P&O\Z^H/^#8
MW_DT/X@_]AH?^B37;_\`!53_`((N:W_P4/\`CII?B[3O&]GX<AT^P%FUO+9F
M9G(_BSFO6/\`@E/_`,$Z=2_X)V?!CQ'X5U+Q+;^)9=<OA=K/#;F$1`1E=N._
MK0V!_.U^U'_R7;XD?]AZ_P#_`$:U?LE_P6>^$%W\0_\`@C?\-=<M8#<'P;IF
MD7TBJ,LJ/:11%A[#=S[5YI\6/^#87Q3\1_B#XGUJ/XJ:9;)K^H7-ZD;::6,0
ME<L%)SSC-?JKH/P0TV?]G;2_AYXB@M];TR#0;?1+Y)$_=W:QP+$QQVSMR/2F
MV!^#/_!`G]JOPY^S'^VK(GBJ^M=+T?QEIQTXW]PP6*WE4[HP3V#,<9KW#_@Y
M5_:\\*?&;4_AYX%\*:[8ZX_A^:?5-1ELIA+%&9$\M8V8<;AMW8]ZZ7X_?\&O
M%U/XSO+SX<>/8+70[J9G@TW4;<F2Q4G(42`_,!T'`QBL;X6_\&NGB>]\70OX
MS^(UG!HR,&G%C`9+BY&>4#$C;QWYI`=)_P`&N'P<O[/3/BAX^GA8:;J7D:39
MR%2`TD6YI,'OU6O-/B;_`,E2US_L*2?^C*_8S]G/]F_PK^RM\'=+\#^#;!=/
MT32HBB#.9)G(^:1S_$Q[FOD'Q7_P1OUKQ%XMU#4E\:V<8O+MKD(;0DJ"^['6
MON^"<WPF"G6>*GR\R5M'TOV3/B^,<LQ6,C26&AS6;OMY=V?3UY_R92__`&+?
M_M*OR7^$?_)6_#O_`&%(O_1@K]D9_A=+-\"F\(?:U$QTS^S_`+1M^7.W;NQ7
MQUX-_P"".>L^%O&6F:H_C2SE6PNTN2@M""X5MV.M=7"V=X+"TL3'$5.5S>FC
MUW[(Y>),HQ>)J8>5"%U%:ZK3;S/?/^"F7_)F7BO_`*YQ_P#H8K\_O^"<W_)Z
MG@;_`*ZS_P#HEZ_3G]JCX)3_`+0WP.UCPE;WZ:;-J:JJW#IO6/!!Z5\Y?LR_
M\$LM5^`GQTT#Q?<^++74(=&>1FMTM2AEW1E>N>.M9</YQ@\/DU?#5IVG+FLK
M/6\4ET[FN>Y5BZ^;4,12A>$>6[TTM*[Z]CY^_P""KO@J[\-_M;WVISQLMMK]
ME!+;-C`;RT"-^M?2O_!,K]IKPEI/[+=IH6L:U8:3>^%FE29+J81LT;,7#@'J
M/F(X]*]J_:J_9-\/?M6^#$T_5_,M-0LR6LK^(9DMF/\`-3Z5\<ZA_P`$8O%E
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MCV!R>:T/^"IG[1WA_P".WQ(T.P\-WT>IZ?X?A??=1',4DC]0I[@`#FNR\6?\
M$7M=AUR==&\56<^FLV8OM,.V1!GA3ZX'>NBO_P#@C)$OP^L+2S\4(FOB9I+R
M[D@S$R'[J(N>,<\]Z^@GFF0_VC'-/;/G:M:SLM+7>G;0\.&79W]0EEWLO=3O
M>ZN];V6O?4A_X(E']W\1?^NME_Z!)7WI7SS^P=^Q3??L?KXF%[KD.M?V^\#I
MY<)C\KRU88/KG=7T-7Y]Q1C*.*S.I7P\N:+M9^D4NI]SPYA:N&RZG1KQM)7N
MOFV%%%%?/GN!1110`'GUJMJ^CVNO:?):WL$=U;RC#QR+E6%6:*:;3N@>NYX'
M\2OV%M-\1SR3Z)JD^ELYW>3(OF)GT!["O*=3_P""<?BR_O"HU?3%A/\`'D[O
MRQ7VD><4A!R!S7MX?B+'48\L97]5<\NODV%JN\HV]&?+_P`,O^"8?AS0[V*\
M\4:E<Z_(A#"W5?)A!]#C[P_*OI70_#UCX9TB&PT^U@L[.W4)'#$@5$`[`5<&
M117%C<SQ6+:>(FY6Z=%Z+8Z<+@:&&35&*7Y_>,-LA).T9-.2,)G`&32T5PW.
ML*",C%%%(!,>YI<<D^M%%`"=">IS7YP?\%[OV!?B;^VO<^`6^'ND0ZH-$$OV
MO?*(]FXG'UK](#GBDYSU-.X'YX?\$$OV$_B3^Q3X?\=0?$+28M+EUFXB>U"2
MA]X'6OT0ZT<C'.:*0!1110`4444`%!&1BBB@``QS01GUHHH`,48P,<T44``!
M'?-&,'.3110`4@!!SDFEHH`3;G@T$9XI:*`#%&.QYHHH`3;]<TN.,<T44`)M
M/')R*-O7DDTM%``!C/?-%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
544`%%%%`!1110`4444`%%%%`'__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>logo2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo2.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!$`#(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_****`"B
MFRRK!&SNP1$&69C@`>IK#A^)>CW5T88+M;AAQF,$K^?0U<82E\*N3*:6[-ZB
MF03K<Q!T;<K=Z?4LJX4444@"@_6BHKZZ%G;/(Q^Z*>^@-GS#^V+^T3+#X]'@
MZPG:.VL8TDU`H<&61AN6,G^ZJX)'J?:L?X7>,)[X.8M[);1F:9^B01@9+L>B
MJ!SDUX1^UI>WFC?M>^*K=P[2:E=07%J,G]XDL2!,?CD5]]_`?X0VWPB^'%EI
MGEI)?2Q+)?S$`M/*1\P_W1T`]!]:^[Q\:&`R^C97<TGZZ)M_B?*8*K5Q>+JZ
MV46U^-DOP/-O"'[=7PRTFY2SO/'>A,YX+HTCQ#_MH%V_K7M_A;Q=I?C?1HM1
MT?4;+5+&<92XM9EEC;\5[^U?,W[<?[#^A^*O#]YXQ\.:=!8:S9`S7]O;QA(K
MZ/\`B?:.!(HYR/O`'/-?._[.WC77_P!F_P`:0ZGI$LITZ9P-0L"Q\F\CSS\O
M0.!DANH/L37/'),'C\*\1@IM36\96W[75OD]?D6\UQ>$Q'L<7!.+V<;[=[._
MS1^F5%4-'\2V6NZ1:7UO<1M!>PI/$20"590PX[<&BOC7&2=FCZ?F3U1?KF?B
M?JK:7H\;9P')&?PKIJR/''A<>,/#D]D7\J1QNBD_N..A^G;\:NA**J)RV)JI
MN+2/D'X^^`=.^)_B[PWK1N;>QU_PU>PO#-.=MO?6PE#M!*P^Z5.2C=!D@\$$
M?9VGZK;:M:K/:W$%S"_*R12!U;\17Q'\;K#5/`VIRVNK6TUK("0C,I\N4>JM
MT(KPOQ)XJNVN?LUC->--,VU8K9W+.?0*O)-??3R6684:<54LHWMI=6>_5'R7
M]I1P56<N2[E:_35'Z0?$#XX>%/#.LV?AN\U.WN-9UV0V<&G0$33L6!R74?=0
M+DDMC@=Z^8&^$84D+'E0>..U:'[#G[&&L>%KZ7QUXJMI;35+B%H-,L9?]=;(
MXP\\GHY4E57J`23CI7T?9_"F*6=?-7;&/O>I'I7D.MALMJ2HX>IS[7?1O7;R
M7SUN>C3C7QL%5KPY>RZVTW_K8\W\,_#S68?#FGHGVD(EM&%`8XP$%%>^PQ+!
M$D:`*B`*H'0`=J*\B6:S;;Y4>DL%%*UQU%%%>4=I6U31[76[8P7EM;W<3=4F
MC$B_D:SM!^'.@>&+DSZ=H>DV$Q/^L@M(XW_,#-;5%6JDTN5-V)<(MW:U"BBB
8H*"BBB@`HHHH`****`"BBB@`HHHH`__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
